Congratulations to GCMI’s very own: Dr. Emily Blum on her recent advancement within Emory University from Adjunct Clinical Instructor to Adjunct Assistant Professor. The advancement is a testament to Dr. Blum’s commitment to education and clinical research. Emily is instrumental in advancing med tech innovation for GCMI. She works tirelessly to promote GCMI in successfully…
We know preclinical testing is a substantial commitment of time and treasure for medtech and life science innovators. We also know the most expensive study is the one you have to do twice. Our response to your request for preclinical work may not be the lowest bottom line price. But please know this: all…
At GCMI and our preclinical testing arm T3 Labs, we take great pride in our scientific acumen. After all, the organization was conceived and designed by translational researchers for medical product developers. Thirst for science: it’s in our DNA. We won’t turn your project away because it’s too hard, or because we haven’t done…
At GCMI, we strive to provide the highest quality data for our preclinical sponsors and customers. GCMI is committed to working with innovators to test medical technologies and therapeutics that consistently meet customer needs and regulatory requirements. We maintain Quality Management Systems to ensure compliance and ongoing quality of our deliverables, products and services.…
Georgia Bio, the state’s life science trade association, named GCMI, the Saldana Research Group and Georgia Tech 2021 Golden Helix Innovation Award recipients. The Innovation Award recognizes the department, institution, company or individuals who are forging new ground by thinking outside traditional paradigms to create some unique technology. In early 2020, U.S. frontline healthcare…
GCMI is proud to announce our Interim CEO, Sherry Farrugia, has been named to the Board of Directors for Medical University of South Carolina Foundation for Research Development (MUSC FRD). “MUSC FRD is pleased to welcome Sherry to the board,” stated Michael Rusnak FRD’s Executive Director of the Board. “Sherry brings over 30 years’…
In the context of GCMI’s phase-gated product development, the “Design and Development” phase (also called “Phase 2” at GCMI) typically follows a Project Planning phase (called “Phase 1” at GCMI). At the completion of project planning, innovators have determined what work is required to take the technology from prototype to product. The Design and Development…
There are approximately 292,000 cases of in-hospital cardiac arrest every year for which the survival rate is less than 24 percent. Resuscitative efforts and supporting technologies are ineffective, slow, fatiguing, traumatic and expensive. As their Fall 2020 Capstone Project, a group of students from the Georgia Tech Schools of Biomedical, Electrical and Mechanical Engineering…
How can medtech, life science and biopharma innovators know their product is ready for preclinical testing? GCMI Design and Development Director Mike Fisher and Preclinical Program Director Evan Goldberg joined Renovo Biomedical’s Anna Fallon on January 14, 2021 to answer that question.
Where does preclinical work find its way into project planning for new medical technologies? What are the top considerations for preclinical work in this early development stage? GCMI Preclinical Program Director Evan Goldberg shares his insights.